Digital Pulse cover art

Digital Pulse

Digital Pulse

By: Pharmatica
Listen for free

Digital Pulse explores AI, data, digital therapeutics, real-world evidence, remote patient monitoring, cybersecurity, clinical workflow automation, interoperability, digital health strategy and the infrastructure behind modern life sciences transformation.Copyright 2026 Pharmatica
Episodes
  • How Pharmacy Innovation Is Changing Healthcare Delivery

    How Pharmacy Innovation Is Changing Healthcare Delivery
    Jun 9 2026
    A product receives market authorisation. It is clinically validated, commercially ready, and genuinely needed. Then it waits for a guideline review, cost evaluation, formulary decisions and three years later, it reaches an NHS patient. For pharma executives who have spent a decade developing that product, the timeline is not a surprise. But it is increasingly a choice, not an inevitability.Judit Mora, CEO and co-founder of Nuumad, joined Trisha Pillay on Digital Pulse to make the case that the route through the NHS is not the only route and that the channel most pharma companies have systematically ignored is precisely where the opportunity sits.The Blindspot That Is Costing Market AccessMora opens with a structural diagnosis that should concern any commercial or market access leader. When products are developed, the thinking defaults to two audiences: the patient and the clinician. Pharmacy which dispenses the product most of the time is an afterthought. This is due to innovation funding following the same logic as product development thinking; the gap compounds."Because this blind spot exists for big pharma, innovation funding doesn't even flow there," Mora says. "It's a self-perpetuating cycle, a lot of tech innovation comes out from incubators run by big pharma, and it's all linked to expectations on their product pipelines."The second failure point is equally familiar to those who have watched digital health initiatives stall: patient-facing innovation built without clinical pathways behind it. Mora's example is Babylon Health, a platform that positioned itself as AI-driven, relied on large volumes of healthcare professionals doing manual work behind the interface, and ultimately couldn't scale because real clinical triage doesn't follow a simple decision tree. "When companies launch 'this is a great patient app', what happens when you actually need clinical intervention? It's always an afterthought."Why the NHS Timeline Is a Strategic Problem, Not Just a Regulatory OneMora is measured about public healthcare systems. They are not broken. They are stretched, and the consequences of that stretch land directly on patient access timelines. The evaluation process the NHS runs is thorough by design: guideline fit is assessed first, cost is scrutinised after, with multiple steps between authorisation and formulary inclusion. For blockbuster products, the biologics in immunology that represent genuine step-changes in patient outcomes, even those remain second-line treatments not because the clinical evidence is weak, but because they are too expensive to deploy at a population scale. "A new product might take three years to get into the NHS and get in front of patients. If you're ill and there's a product that will change your quality of life, that's a significant burden."The private route Nuumad operates within doesn't displace the NHS pathway. It runs alongside it. Get an independent medical evaluation, make the product available through pharmacies or private clinics, and let patients who want earlier access make that choice. "It's a much quicker market access, and it opens up the possibility." The equity question is real, and Mora acknowledges it. But availability is a precondition for access of any kind.The Mechanism: A Prescription Without a PrescriptionThe model Nuumad has built centres on a Patient Group Direction, the same legal framework that enables NHS flu and COVID vaccination services to be delivered by pharmacy technicians and nurses without individual prescriptions. A PGD defines inclusion and exclusion criteria; a clinician who works through those criteria can dispense the product directly. No GP referral. No prescriber in the chain.What Nuumad adds is the clinical user experience layer that turns that legal document into a functional digital platform, one that guides a pharmacist or pharmacy technician through a gold-standard consultation, building clinical confidence as it does. "What we want to do is instil process thinking, even for non-prescribing clinicians who may have never run these types of services." The design goal is explicit: the platform should reduce anxiety, not create it. A clinician using it for the first time should feel guided, not exposed.On AI: Why Nuumad Is Deliberately Not Going ThereMora's position on AI in clinical workflows is a useful corrective to the current market noise. Nuumad uses AI for operational purposes only. Clinical decision support runs on deterministic, rule-based algorithms, and the reasoning is worth understanding. AI outputs vary when models are retrained or updated. In a clinical decision context, that inconsistency is not acceptable. European healthcare data models differ materially from the US datasets most large AI systems are trained on. And critically, AI tools in clinical settings still require human validation, which undermines the efficiency case entirely. "If you outsource your own healthcare thinking to a tool that may not give you ...
    Show More Show Less
    29 mins
  • How AI and Digital Innovation Are Reshaping Clinical Trials in HealthTech

    How AI and Digital Innovation Are Reshaping Clinical Trials in HealthTech
    Jun 8 2026
    Across many parts of Africa, clinical research still depends heavily on paper-based workflows. For pharmaceutical companies managing global trial portfolios, this can create operational challenges around data quality, monitoring, and regulatory readiness, particularly when studies contribute to submissions in the US and Europe.Adriaan Kruger, founder and CEO of nuvoteQ has spent twelve years building the infrastructure to close that gap. His conversation with Trisha Pillay on Digital Pulse is one of the more candid accounts available of what digital adoption in clinical research actually looks like when the constraints are real.Why Paper Persists and What It Actually CostsThe persistence of paper in LMIC clinical research settings is not a technology problem. The technology exists."Our industry is so hesitant and so resistant to change," he says. "They are so risk-averse — which we totally get in this highly regulated world. These researchers are so worried about potentially using a system and then the data gets lost, or the system is down. So they go back to their tried and tested way of doing things, which is on paper."The financial dimension compounds the risk-aversion. Funding does not flow to research sites in sufficient volumes to support digital infrastructure investment. The result is double data entry, a risk mitigation practice where patient data recorded on paper is manually typed into a centralised system twice by different operators, then compared for discrepancies. In developed markets, this practice has largely been eliminated. Across much of Africa, it remains the norm.The downstream cost is significant as data science teams spend extensive time converting inconsistent paper records, Excel files, and incorrectly formatted entries into globally standardised formats before a single submission can be filed.Real-Time Visibility Changes the Risk CalculationThe operational case for digital infrastructure is sharpest when Kruger describes what real-time data visibility actually enables at the trial level. Clinical trials running across multiple countries like South Africa, Mozambique, Ghana, Finland, and Australia simultaneously have historically operated with delayed information flows. A serious adverse event occurring overnight in South America might take days to trigger a coordinated global response. The pharmaceutical company, the investigators, and the data safety monitoring board are all operating on different information timelines."If they don't have real-time data, often there's a delayed reaction on how you deal with things," Kruger says. "Now if they have a real-time view of everything happening globally, they can make insightful decisions, let's pivot, let's change the dosage, or there was a serious adverse event, it happened last night in South America. The morning we wake up, everyone knows."For pharma executives managing trial costs, trials are expensive precisely because they run long, across many sites, with significant overhead. The ability to make earlier decisions about dosage adjustment, site performance, or trial termination is a direct cost lever. "You can make decisions on whether to move faster, change direction, or potentially stop a study so that you don't spend more money on it."AI Where It Works in Clinical ResearchKruger's position on AI in clinical research is one of the more technically grounded takes in the current conversation. nuvoteQ is not AI-averse, but the firm is precise about where AI delivers and where the industry's enthusiasm is running ahead of its readiness.The clearest proof point is a regulatory review tool built for South Africa's medicines regulator, SAHPRA, in partnership with a Seattle-based philanthropic funder. The challenge was a generic drug dossier, submissions that can run to 15,000 pages, were sitting in regulatory queues for up to nine years across Africa, delaying the availability of affordable medicines for the patients who need them most.The tech company deployed an open-source LLM locally within SAHPRA's data centre, with no external internet access, trained to analyse dossiers and produce a two-page risk summary with hyperlinked references to the source document. "That has reduced the timeline to review from where it typically takes five to six weeks. We can do it in about 45 minutes now."The model works because the data never leaves a closed environment, the task is well-defined and repetitive, and human reviewers remain in the loop for final decisions. That last point is deliberate. "You will always have a human in the loop. There will always be a healthcare professional. AI will help do some of the number crunching, but ultimately, when it comes to patient care, the ethical component is how patients are being treated. I don't think AI is going to be there for a long time."The liability question Kruger raises for clinical AI tools mirrors what is emerging elsewhere in regulated industries: the responsibility for an AI-assisted...
    Show More Show Less
    31 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet